GSK announces US FDA approved prefilled syringe presentation of SHINGRIX

GSK (GSK) announced that the US Food and Drug Administration, FDA, has approved a prefilled syringe presentation of SHINGRIX for the prevention of shingles. The new prefilled syringe removes the need to reconstitute separate vials prior to administration, simplifying the vaccine administration process for healthcare professionals. The existing vaccine presentation consists of two vials, a lyophilized antigen and a liquid adjuvant, which healthcare professionals combine prior to administering. The approval of the new presentation is based on data demonstrating technical comparability between the new and existing vaccine presentation